The announcement
Australian biotechnology company BresaGen Ltd today received
clarification about proposed changes to export and customs
regulations following the recent Senate approval of Bills for
Research Involving Embryos and Prohibition of Human Cloning.
The company has been informed by the National Health and Medical
Research Council that there is no intention to prohibit the export of
embryonic stem cells or the products of embryonic stem cells.
The regulatory changes only are intended to stop the export of whole
embryos. BresaGen is encouraged by such an approach, as these changes
will not hinder the development of embryonic stem cell based
therapies in Australia for export to world markets.
BGN
bresagen limited